Humana shares plunged 13.49% in premarket trading following the Trump administration’s proposal for nearly flat Medicare Advantage payment rates in 2027, offering just a 0.09% net average increase versus Wall Street’s 4–6% expectations. The announcement dragged down the broader health insurance sector, with UnitedHealth Group off 8.2%, CVS Health down 7.5% and Elevance Health falling 9.1%. Analysts warn that constrained rate growth could cut Humana’s Medicare Advantage operating margin by an estimated 150–200 basis points in 2027, potentially reducing annual adjusted EBITDA by up to $1.2 billion. Investors will be watching Humana’s cost management initiatives and membership growth in dual-eligible plans to offset reimbursement headwinds.

Humana has established a $3 million scholarship fund in partnership with Xavier Ochsner College of Medicine to increase the number of primary care physicians serving underserved communities in Louisiana. The program will provide full-tuition scholarships and stipends to up to 30 medical students over the next five years, with a matching requirement for recipients to complete at least three years of practice in high-need parishes. Humana projects that boosting local physician capacity could reduce avoidable emergency department visits by as much as 12% and lower overall healthcare costs in the region by up to $45 million annually within a decade.

Humana has launched a nationwide partnership with Carda Health to offer virtual, home-based cardiac rehabilitation (HBCR) to members recovering from acute cardiovascular events. Carda, the largest provider of virtual cardiac and pulmonary care, will deliver live-monitored exercise sessions, nutrition counseling and medication follow-ups via its proprietary digital platform. The program targets Humana members who face barriers to traditional facility-based rehab—such as transportation and mobility challenges—and is expected to enroll 15,000 participants in its first year. Humana anticipates that expanding access to HBCR could cut 30-day hospital readmission rates by up to 25% and generate annual cost savings of $150–200 million through reduced acute care utilization.